US Patent 7230032 Calcium blockers to treat proliferative vitreoretinopathy

Patent 7230032 was granted and assigned to Allergan, Inc. on June, 2007 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Current Assignee

Allergan, Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

72300320

Patent Inventor Names

Evan B. Dreyer0

Date of Patent

June 12, 2007

Patent Application Number

104369020

Date Filed

May 12, 2003

Patent Primary Examiner

‌

Zohreh A Fay

Patent abstract

Glutamate causes migration and proliferation of retinal pigment epithelium and/or glial cells, and glutamate antagonists can prevent, treat or reduce retinal pigment epithelium and/or glial migration and the subsequent development of proliferative vitreoretinopathy. Avoidance or management of proliferative vitreoretinopathy can be achieved by administering to the patient a compound capable of reducing glutamate-induced retinal cell migration in a concentration effective to reduce such migration.